{"altmetric_id":24221624,"selected_quotes":["New cancer clinical trial: Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed\/Refractory B-cel\u2026"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )"],"first_seen_on":"2017-08-23T12:50:02+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1503494210,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03258593?term=cancer&lup_s=08\/09\/2017&lup_d=14&show_rss=Y&sel_rss=mod14"],"nct_id":"NCT03258593","pubdate":"2017-08-22T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed\/Refractory B-cell Malignancies","type":"clinical_trial_study_record"},"altmetric_score":{"score":0.75,"score_history":{"1y":0.75,"6m":0.75,"3m":0.75,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.75},"context_for_score":{"all":{"total_number_of_other_articles":8418826,"mean":7.0849522326371,"rank":6086762,"this_scored_higher_than_pct":24,"this_scored_higher_than":2030389,"rank_type":"exact","sample_size":8418826,"percentile":24},"similar_age_3m":{"total_number_of_other_articles":169963,"mean":12.724714336146,"rank":110379,"this_scored_higher_than_pct":28,"this_scored_higher_than":49265,"rank_type":"exact","sample_size":169963,"percentile":28},"this_journal":{"total_number_of_other_articles":24831,"mean":10.521629963753,"rank":16535,"this_scored_higher_than_pct":30,"this_scored_higher_than":7675,"rank_type":"exact","sample_size":24831,"percentile":30},"similar_age_this_journal_3m":{"total_number_of_other_articles":877,"mean":2.7282876712329,"rank":520,"this_scored_higher_than_pct":28,"this_scored_higher_than":251,"rank_type":"exact","sample_size":877,"percentile":28}}},"demographics":{"poster_types":{"member_of_the_public":3},"users":{"twitter":{"cohorts":{"Members of the public":3}}},"geo":{"twitter":{"IN":1,"US":1}}},"counts":{"total":{"posts_count":3},"twitter":{"unique_users_count":3,"unique_users":["xeroxnet69","JROSENBERG1","DonJohnstonLC"],"posts_count":3}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/xeroxnet69\/statuses\/900339287211880448","license":"gnip","citation_ids":[24221624],"posted_on":"2017-08-23T12:49:48+00:00","author":{"name":"\u4e02\u03b1\u0399\u03b9\u039c \u03b1\u0399\u03b9","image":"https:\/\/pbs.twimg.com\/profile_images\/900546423539736576\/vZvnPZTQ_normal.jpg","description":"An Android Enthusiasts from Assam, IN he loves to Explore-Gain-Share Technology news and Interact with people.\nInstagram : @imsalimali","id_on_source":"xeroxnet69","tweeter_id":"779945586409762817","geo":{"lt":20,"ln":77,"country":"IN"},"followers":27},"tweet_id":"900339287211880448"},{"url":"http:\/\/twitter.com\/JROSENBERG1\/statuses\/900339994572632066","license":"gnip","citation_ids":[24221624],"posted_on":"2017-08-23T12:52:36+00:00","author":{"name":"JROSENBERG","url":"http:\/\/www.thebiggestnews.com","image":"https:\/\/pbs.twimg.com\/profile_images\/878105235683774472\/hhC8B7WO_normal.jpg","description":"http:\/\/THEBIGGESTNEWS.COM \nThe Biggest News Ever!","id_on_source":"JROSENBERG1","tweeter_id":"20725212","geo":{"lt":null,"ln":null},"followers":1634},"tweet_id":"900339994572632066"},{"url":"http:\/\/twitter.com\/DonJohnstonLC\/statuses\/900346093346729984","license":"gnip","citation_ids":[24221624],"posted_on":"2017-08-23T13:16:50+00:00","author":{"name":"Don Johnston (LC)","url":"https:\/\/LimaCharlieNews.com","image":"https:\/\/pbs.twimg.com\/profile_images\/899843960767643648\/x30pTAZ9_normal.jpg","description":"Don Johnston | Co-Founder @LimaCharlieNews                             Entrepreneur | U.S. Army Combat Veteran           \nNonpartisan | Your Feelings \u2260 Reality","id_on_source":"DonJohnstonLC","tweeter_id":"736680450580721664","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":2688},"tweet_id":"900346093346729984"}]}}